The Effectiveness of Pharmaceutical Service for INPATDRP
ConditionDrug Related Problem
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-100
SponsorZhejiang Provincial People's Hospital
About this trial
Medication risk is defined as the potential for loss or harm that may result from the use of medications during the course of treatment. Drug-related problems (DRPs) are defined as events or situations involving drug therapy that actually or potentially interfere with desired health outcomes. DRPs represent a significant aspect of medication risk in hospitalized patients, and the study and management of DRPs can effectively reduce the incidence of medication risk. DRPs are associated with both therapeutic efficacy and adverse drug events, and the timely identification and reduction of DRPs can enhance clinical efficacy and prevent the occurrence of adverse events.
DRPs pose a challenge to the clinician, and that may affect patient's clinical outcomes and may result in morbidity or mortality and increased health care costs. Health care costs may become a burden to the patient or may be to the government or to the third parties. Clinical Pharmacy is a discipline that promotes the quality use of medicines through evidence-based medicine and helps in identification and resolving DRPs. A clinical pharmacist through his/her clinical accuracy checking may identify DRPs and come out with suitable solutions to resolve the same.
Consequently, the aims of our study were to investigate the efficacy and safety effects of pharmacist-implemented drug-related problems (DRPs)-based interventions on patients' medication therapy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Hospitalized patients;
Hospitalization duration >3 d;
Adult patients aged ≥18 years and ≤100 years (only adult patients aged 18 years or older were included in the medication management study because of the difference in study methodology between minor and adult patients);
Patients or close relatives gave informed consent and were willing to communicate with the clinical pharmacist and receive medication life education.
Disqualifiers
Those who did not meet the inclusion criteria;
Patients who are in the acute phase of the disease requiring emergency medical consultation;
Those with any serious or life-threatening diseases (heart, lung, liver, kidney failure, hematologic diseases, malignant tumors, etc.);
Patients with psychiatric disorders, hearing impairments, intellectual disabilities, aphasia, etc. that make them unable to communicate or comply with the study protocol;
Trial design
Design model
Parallel
Treatments tested in this trial
Clinical Pharmacist-led Pharmaceutical Services
BehavioralPharmacists developed an intervention plan to reduce DRPs and improve patients' quality of life by assessing patients' medication knowledge, drug-related problems, and adherence problems in the intervention group in the order of urgency, importance, and priority to be addressed. The plan included a list of patients' medication or lifestyle-related problems, a list of programs based on the assessed problems, and other information.
Treatment groups
220 Participants
are divided into 2 treatment groupsGroup A: Clinical Pharmacist-led Pharmaceutical ServicesExperimental treatment 1 intervention
Group B: Usual careNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
Number of DRPs
Number of drug related problems identified in inpatient
Time frame
One year from inclusion2
Change in DRPs
Determination of drug-related problems (DRP) using Pharmaceutical Care Network Europe (PCNE) Version 9.1. The basic classification has 3 primary domains for problems, 9 primary domains for causes and 5 primary domains for Planned Interventions, 3 primary domains for level of acceptance (of interventions) and 4 primary domains for the Status of the problem.
Time frame
One year from inclusionSecondary outcomes
1
Medication Adherence
The Morisky Adherence Scale was used, with scores less than 6 being low adherence, 6-7.75 being moderate adherence, and 8 being high adherence.
Time frame
One year from inclusion2
Patients' knowledge
Using the medication knowledge evaluation tool, medication knowledge evaluation questionnaire with 7 questions,The patient scores 1 point if he/she knows the correct answer, 0 points if he/she does not know and -1 if the information given is incorrect. Score goes from -7 (patient who answers all questions incorrectly) to 7 (patient who answer all questions correctly) for each medication that the patient is taking. A score of 0 has no particular significance, apart from being in the middle of the two extremes.
Time frame
One year from inclusion3
Patient satisfaction in the experimental group
Patient satisfaction in the intervention group was assessed using a patient satisfaction questionnaire.
Time frame
One year from inclusionSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: